Mindmaze Therapeutics Holding Sa · SIX:MMTX
Mindmaze Therapeutics Holding Sa — Investor Presentation (March 2026)
20 slides from Mindmaze Therapeutics Holding Sa's investor presentation, March 2026
Slide 1: Improving the lives of people with brain disorders through evidence-based, AI-powered neurotherapeutics
Improving the lives of people with brain disorders through evidence-based, AI-powered neurotherapeutics Investor presentation March 2026
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer to sell or issue, or any solicitation of an offer to purchase or subscribe for, any securities. Neither this presentation nor its distribution shall form the basis of, or be relied upon in connection with, any contract or inv
Slide 3: Introducing MindMaze Therapeutics
Introducing MindMaze Therapeutics Our mission Redefine the future of brain health and recovery to change patient lives By providing precision neurotherapeutics and a unique closed-loop ecosystem 25+ Patents 27 Completed 12 Regulatory granted clinical clearances Across the full continuum-of-car
Slide 4: Business overview
Business overview A first-of-its-kind precision Proven results with tangible Scalable growth powered neurology ecosystem milestones achieved by a flywheel effect Fully developed integrated suite Value Proposition to Providers Treatment personalization Clinically validated Real-World InClinic O
Slide 5: Addressing the unmet needs of major markets in neurology
Addressing the unmet needs of major markets in neurology The unsustainable burden of neurological diseases - US market data (estimate) Dementia Traumatic brain Parkinson’s Indication Stroke incl. Alzheimer’s and spinal injury disease Prevalence ~7m ~6m ~6m ~1m Economic costs (2024E) (direct + indire
Slide 6: Seamlessly integrated neurotherapeutic suite of solutions
Seamlessly integrated neurotherapeutic suite of solutions AI-driven platform DIGITAL NEUROTHERAPEUTICS In-clinic / outpatient Outpatient / home MindPod MindMotion GO Software-delivered clinical Reducing Improving intervention for cognitive impairment function and motor training Immersive neuro-behav
Slide 7: End-to-end platform spanning the continuum of care
End-to-end platform spanning the continuum of care With MMTX suite Illustrative functional performance Standard of care Pre-impact Impact Acute care Sub-acute Chronic Aging Clinical protocols In-patient Outpatient At home Impairment reducing, function enhancing: Function enhancing: Remote Therapist
Slide 8: Clinical and real-world evidence
Clinical and real-world evidence Clinical evidence Stroke Parkinson’s At-Risk Aging • 27 completed studies / 13 on going studies N = 81 N = 90 N = 229 • Demonstrating In-clinic Upper Limb Gait, Balance, Cognition, Cognition and improvements in upper- immersive treatment • +14-19.6pts in Fugl-Meyer F
Slide 9: Economic value: 80% cost saving
Economic value: 80% cost saving Our platform enables significant and quantifiable cost savings Standard 1:1 therapy MindMaze training US$1,903 82% US$338 PER PATIENT Cost savings PER PATIENT 100% therapist utilization 20% therapist utilization (80% patient self-training) Based on 36 hours of trainin
Slide 10: Growth strategy to tap the massive market potential
Growth strategy to tap the massive market potential Walk the plan to address market needs Expand footprint across market segments 1. Healthcare providers and payers • Validated value proposition • Unique at-home reimbursement • Ability to replicate at scale • Objective to expand in Europe 2. Pharmac
Slide 11: US providers: A scalable platform ready for deployment
US providers: A scalable platform ready for deployment Successful deployment Across the continuum of care No. of patients (across 5 VIBRA centers) • Multi-site commercial deployment of HDHI 178 clinical program • End-to-End: covering inpatient, outpatient and Home home 337 InPatient • Across neurolo
Slide 12: EU payers: Broaden market access through reimbursement
EU payers: Broaden market access through reimbursement Focused on obtaining Flagship project of Innosuisse the reimbursement for A solid established at-home utilization footprint A paradigm shift in neurorehabilitation • Switzerland: SwissNeuroRehab Integrative, patient-centered model that spans the
Slide 13: Pharma partnerships: Multi-faceted value proposition
Pharma partnerships: Multi-faceted value proposition 1 1 2 3 Next big thing Enable “Around the Pill”/Pill+ strategies Accelerate “Data Play” strategies through Enable “Beyond the Pill” strategies through through the promotion of drugs with its assessment solution and monitoring the co-development of
Slide 14: AI-Engine: Transform data into actionable insights
AI-Engine: Transform data into actionable insights Towards a generalized and autonomous system • Gen-AI based Patient-Personalized Content and Therapy • Exploration of Combination of Drugs + Neurotherapeutics Efficacy • Automation of Triage & Prescription • Autonomous Therapy System Streamlined usag
Slide 15: Management expectations: Revenue > CHF200m by 2031
Management expectations: Revenue > CHF200m by 2031 Business pillars Revenue 2027E > CHF 40m Providers/Payers Pharma Partnerships AI Platform CAGR 2027-2031E: > 40% p.a. Geography US/Global Global US/Global Approximately 35,000 since launch Commercial expansion 20 major targets powered by AI Est. # u
Slide 16: Leadership expertise across healthcare and technology
Leadership expertise across healthcare and technology Board of Directors Walid Nazir Hanna Olaf Blanke Martin Reiss Chairman Member Member Executive Management Team Zach Henderson Alexander Capet Frederic Condolo Jeremy Meinen Paolo Galfetti CEO COO CTO CFO CBO MBA Villanova University MSc Sciences
Slide 17: Business combination update
Business combination update Maximize shareholder value by monetizing legacy assets while focusing resources on scaling the neurotherapeutics platform 1 2 3 Combination strategy Cost optimization Asset monetization • Focus capital and execution on scaling • Talents to be transferred to MindMaze RLF-O
Slide 18: Financial profile
Financial profile Public capital market access and available funding options supporting commercial expansion Liquidity and funding options Listing and capital structure • CHF 6.3 million cash as of March 1, 2026 • Traded on SIX Swiss Exchange: MMTX • Cash runway through Q2 2026 • Evaluating potentia
Slide 19: Company update & near-term catalysts
Company update & near-term catalysts Completion 2026 (est.) Growth of the US customer footprint Progressing negotiations with providers and commercial partners Q1 - Q2 Commercial Expansion of the US commercial organization Recruitment plan in place Q2 Development of collaborations with pharma Finali
Slide 20: Uniquely positioned in neurology to create significant value
Uniquely positioned in neurology to create significant value • Unsustainable burden of neurological diseases PROBLEM • Unattainable medical guidelines by lack of resources and fragmentation of care • AI-driven tech stack to deliver at scale behavioral high-dose, high-intensity treatment SOLUTION • E
MindMaze Therapeutics Holding — Investor Presentation (March 2026) on 6ix